Skip to main content
Tetra Bio-Pharma Inc. logo

Tetra Bio-Pharma Inc. — Investor Relations & Filings

Ticker · TBPMQ ISIN · CA88166Y1007 LEI · 5299000CYH3P8XC2UO53 TSX Manufacturing
Open in API
Filings indexed 720 across all filing types
Latest filing 2020-10-15 Interim / Quarterly Rep…
Country CA Canada
Listing TSX TBPMQ

About Tetra Bio-Pharma Inc.

https://tetrabiosciences.com/

Tetra Bio-Pharma is a biopharmaceutical company specializing in the discovery and development of cannabinoid-derived drugs and medicinal plant-based products. The company maintains an advanced pipeline encompassing biopharmaceuticals, natural health, and veterinary products. Clinical programs are focused on therapeutic areas such as inflammation, pain management (including alternatives to opioids), and ophthalmology. Tetra emphasizes rigorous clinical trials and scientific evidence, utilizing novel approaches, unique mechanisms of action, and high-quality delivery methods to address unmet patient needs.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS' for the nine months ended August 31, 2020. It contains detailed financial statements including Statements of Financial Position, Loss and Comprehensive Loss, and Changes in Shareholders' Equity. The presence of unaudited condensed interim financial data for a period shorter than a full fiscal year (nine months) and substantive financial data confirms this is an Interim / Quarterly Report. The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement or certification. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). 9M 2020
2020-10-15 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release from Tetra Bio-Pharma providing an update on its commercial strategy related to chemotherapy induced nausea and vomiting (CINV) drug development and marketing plans. It discusses upcoming regulatory submissions, commercial plans, and product pipeline details. There are no financial statements, detailed financial performance data, or comprehensive management analysis typical of annual or interim reports. It is not a transcript of a call, nor an audit or legal proceeding report. The document is primarily a corporate announcement about commercial strategy and product development progress, which fits best under Capital/Financing Update (CAP) as it relates to the company's commercial operations and regulatory submission plans that impact capital and financing outlook. The document length is 8946 characters, which is substantial but the content is clearly an update/announcement rather than a full financial report or presentation. Therefore, the most appropriate classification is CAP with high confidence.
2020-10-07 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing Tetra Bio-Pharma's acquisition of exclusive Canadian distribution rights for Dronabinol Soft Gel capsules. It discusses the strategic business move, expected regulatory submissions, and commercial plans. There are no financial statements, quarterly or annual results, nor detailed financial data or management discussion of financial performance. The content focuses on a capital transaction and business update related to financing and commercial rights acquisition. Therefore, it fits best under Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing-related acquisition, not merely an announcement of a report or regulatory filing.
2020-09-30 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of two new board members and a new Chief Operating Officer at Tetra Bio-Pharma. It details the professional backgrounds of the new appointees and the company's strategic direction. There is no financial data, no mention of a report or filing, no voting results, no regulatory or legal updates, and no discussion of financial performance or capital changes. The content is focused on management and board changes, which fits the category of Board/Management Information (MANG). The document length is over 10,000 characters, indicating it is a full announcement rather than a brief notice or report publication announcement.
2020-09-17 English
News release - English.pdf
Regulatory Filings
2020-09-11 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Dania Scott as Senior Vice President Commercial Strategy at Tetra Bio-Pharma. It focuses on management changes and the strategic role of the new executive. There is no financial data, no report or regulatory filing referenced as attached or published, and no mention of voting results, dividends, or other financial events. The content is clearly about a change in senior management personnel, which fits the Board/Management Information category (MANG). The document length is 7120 characters, which is sufficient for a detailed announcement but does not contain financial statements or report data. Therefore, the correct classification is MANG with high confidence.
2020-09-04 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.